Current Nutrition Reports

, Volume 2, Issue 4, pp 258–266

Consumption of Nuts in the Prevention of Cardiovascular Disease

Authors

    • Department of Nutrition, School of Public HealthLoma Linda University
    • Department of Epidemiology and BiostatisticsLoma Linda University
  • Michelle Wien
    • Department of Nutrition, School of Public HealthLoma Linda University
Cardiovascular Disease (L Djoussé, Section Editor)

DOI: 10.1007/s13668-013-0059-x

Cite this article as:
Sabaté, J. & Wien, M. Curr Nutr Rep (2013) 2: 258. doi:10.1007/s13668-013-0059-x

Abstract

The leading cause of morbidity and mortality in highly developed and low- and middle-income nations is cardiovascular disease (CVD). The establishment of healthy dietary patterns is one of the cornerstones of CVD prevention, and nuts have emerged as favorable components of dietary patterns associated with reducing the CVD epidemic. The etiological connection between nuts for the prevention of CVD is based upon several lines of evidence. First, nuts are nutrient-dense whole foods that contain a distinctive mix of macronutrients, specific micronutrients and non-nutrients that have been associated with cardioprotection. Second, numerous human feeding trials have demonstrated that nut intake improves the serum lipid profile, reduces oxidation and inflammation, and improves vascular reactivity. Third, nut consumption is consistently associated with a reduced risk of CVD in many epidemiological studies. Lastly, a recent large randomized clinical trial conducted in Spain demonstrated that consuming mixed nuts daily lowers CVD risk by 30 %.

Keywords

NutsLipidsCholesterolFatty acidsPhytochemicalsAntioxidantsCardiovascularMortalityHypertensionInflammationEndothelial function

Introduction

Significant strides have been made since the 1970s to reduce the complications and mortality associated with cardiovascular disease (CVD) in highly developed nations. However, CVD still remains the leading cause of deaths worldwide due to the concurrent rise and disproportionate burden of CVD in low- and middle-income nations [1•]. Advancing age, gender and family history are indisputable risk factors that contribute to the development of CVD; therefore, modifiable lifestyle risk factors are targeted in public health messages for the primary prevention of CVD. The establishment of healthy dietary patterns is one of the cornerstones of CVD prevention, and tree nuts have emerged as favorable components of healthy dietary patterns associated with diminishing CVD risk.

In the nut family, 10 are botanically classified as tree nuts: almonds, Brazil nuts, cashews, chestnuts, hazel nuts, macadamias, pecans, pine nuts, pistachios, and walnuts. Chestnuts differ significantly from the other nine common tree nuts due to their higher carbohydrate content, whereas peanuts, which are botanically classified as legumes, have a very similar nutrient profile to the nine common tree nuts. Thus, for this review paper we are operationally defining “nuts” to include the nine common tree nuts plus peanuts.

Composition of Nuts and CVD

In light of their unique macronutrient, micronutrient and non-nutrient bioactive constituents [2], nuts are nutrient-dense whole foods that confer cardioprotection. Nuts contain significantly larger amounts of unsaturated fatty acids (UFA), e.g., monounsaturated fatty acids (MUFA) and polyunsaturated fatty acids (PUFA), as compared to saturated fatty acids (SFA), which results in a preferential UFA:SFA ratio of ~3:12 (Table 1). Further, walnuts contain the highest level of alpha-linolenic acid (ALA) among all plant sources, which is the n-3 fatty acid that has been shown to exert cardioprotection through the reduction of platelet aggregation, vasoconstriction and inflammation [3, 4]. Nuts are also a good source of plant protein (~8–26 g per 100 g) and most nuts are rich sources of the amino acid L-arginine [5], which is the precursor of the powerful endogenous vasodilator nitric oxide (NO) [6]. In light of their high arginine content, a preferentially low arginine to lysine ratio between 0.01 and 0.57 is found in nuts, which can contribute towards reducing plasma low density lipoprotein (LDL) levels [7, 8]. The very low glycemic index of nuts (<15) is due in part to their low carbohydrate content (12–30 g per 100 g) in the context of their dietary fiber content (~3–12 g per 100 g) [9].
Table 1

Nutrient composition of nine commonly consumed tree nuts and peanuts per 100 g

 

CHO, g

Fiber, g

Protein, g

Fat, g

SFA, g

MUFA, g

PUFA, g

UFA: SFA

α-toc, mg

γ-toc, mg

K, mg

Mg, mg

Phytosterol, mg

Almonds

21.67

12.2

21.22

49.42

3.731

30.889

12.070

11.51

26.22

0.65

705

268

31.0

Brazil nuts

12.27

7.5

14.32

66.43

15.137

24.548

20.577

2.98

5.73

7.87

659

376

21.5

Cashews

30.19

3.3

18.22

43.82

7.783

23.797

7.845

4.07

0.90

0.03

660

292

-

Hazelnuts

16.70

9.7

14.95

60.75

4.464

45.652

7.920

12.00

15.03

0.00

680

163

12.0

Macadamia

13.82

8.6

7.91

75.77

12.061

58.877

1.502

5.01

0.54

0.00

368

130

-

Pecans

13.86

9.6

9.17

71.97

6.180

40.801

21.614

10.10

1.40

24.44

410

121

32.8

Pine nuts

13.08

3.7

13.69

68.37

4.899

18.764

34.071

10.78

9.33

11.15

597

251

84.1

Pistachios

27.51

10.3

20.27

45.39

5.556

23.820

13.744

6.76

2.30

22.60

1025

121

-

Walnuts

13.71

6.7

15.23

65.21

6.126

8.933

47.174

9.16

0.70

20.83

441

158

18.2

Peanuts

16.13

8.5

25.80

49.24

6.834

24.429

15.559

5.85

8.33

-

705

168

-

Values taken from U.S. Department of Agriculture, Agricultural Research Service. 2012. USDA National Nutrient Database for Standard Reference, Release 25. Nutrient Data Laboratory Home Page, http://www.ars.usda.gov/ba/bhnrc/ndl (accessed 12 July 2013)

CHO carbohydrate, MUFA monounsaturated fatty acid, PUFA polyunsaturated fatty acid, UFA unsaturated fatty acid, SFA saturated fatty acid, α-toc alpha-tocopherol, γ-toc gamma-tocopherol K potassium, Mg magnesium

Nuts contain significant amounts of bioavailable antioxidants, i.e., tocopherols and bioactive compounds, including phytochemicals, phytoestrogens and phytosterols, that have the ability to be cardioprotective through various mechanisms [10]. Notably, almonds and hazelnuts have the highest levels of α-tocopherol, whereas pecans, pistachios and walnuts contain significant levels of γ-tocopherol. Additionally, the phytosterol content of nuts may partially inhibit the absorption of dietary cholesterol and recirculating endogenous biliary cholesterol in the intestinal lumen, and may be associated with reductions in plasma cholesterol and CVD prevention [11].

Nuts are rich in several cardioprotective minerals. Reductions in blood pressure were observed from the intake of the Dietary Approaches to Stop Hypertension (DASH) dietary pattern [12], which included nuts and other nutrient-dense whole foods. More specifically, a low sodium intake in the context of a high intake of magnesium, potassium and calcium using the DASH pattern was associated with reductions in systolic and diastolic blood pressure by 6 and 3 mm Hg, respectively, in patients with pre-hypertension, and reductions of 11 and 5 mm Hg, respectively, in hypertensive patients. Further, unprocessed nuts are whole foods that contain negligible amounts of sodium, and many are rich sources of magnesium, potassium and copper [13], which are associated with the prevention of ventricular arrythmias and reductions in arterial hypertension [14, 15].

Summary Statement for Composition of Nuts and CVD

The composition of nuts shown in Table 1 lists several of the macronutrients, specific micronutrients and non-nutrients that have been associated with cardioprotection. To achieve optimal health outcomes (e.g., CVD reduction), one of the recommendations given in the 2010 Report of the Dietary Guidelines for Americans is to shift to a more plant-based dietary pattern that includes nuts. Thus, unprocessed nuts are an appropriate whole food to include within a prudent diet to decrease the prevalence of CVD in populations.

Nut Consumption Intervention Trials and CVD Risk Factor Outcomes

Over 40 nut feeding trials in humans have been conducted worldwide since the findings from a tightly controlled metabolic feeding study performed at Loma Linda University were published in the New England Journal of Medicine [16]. This investigative team found 12 and 18 % reductions in serum total cholesterol (TC) and LDL cholesterol levels, respectively, from the consumption of a walnut-enriched diet (20 % of energy from walnuts) compared with a healthy American Heart Association “Step One” diet (10 % energy from SFA, 10 % energy from MUFA, 10 % energy from PUFA, and 250 mg cholesterol per day). Ten years later, in response to the emerging scientific research that demonstrated the beneficial effects of nut consumption on CVD risk factors, the United States (US) Food and Drug Administration (FDA) released a qualified health claim [17] stating that “Scientific evidence suggests but does not prove that eating 1.5 ounces per day of most nuts, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease.”

Human feeding studies have typically been of short-term duration (3–8 weeks) and have been performed on healthy subjects or on moderately hypercholesterolemic patients. The “control” diet for testing the effect of the nut intervention(s) has been the Western (high in saturated fat), Mediterranean, or low saturated fat diet. Also, the most commonly studied nuts have been almonds and walnuts, and there have been no studies conducted using pine nuts to date.

Effect of Nuts on Blood Lipid Levels

Recently, a pooled analysis of 25 nut feeding trials that were published up to December 2004 was conducted to evaluate the effects of nuts on blood lipid levels, and to determine if these effects remained consistent after stratification by gender, age, body mass index, type of nut, degree of dietary compliance, type of control diet and source of study funding [18••]. This pooled analysis of 583 unique subjects and 1,284 observations from seven countries found that the mean intake of 67 g per day of nuts produced a 5.1, 7.4 and 8.3 % mean estimated reduction in TC, LDL cholesterol and ratio of LDL:HDL, respectively. Null effects were shown for high-density lipoprotein (HDL) cholesterol and triglycerides (TG), with the exception of subjects with TG levels greater than 150 mg/dl who experienced a significant TG reduction of 20.6 mg/dl (10.2 %). An important finding was that the lipid lowering effects of consuming 10, 12.2 (43 g/d as recommended by the USFDA qualified health claim) and 20 % energy from nuts were dose-related. Further, the effects were found to be greater in subjects with a lower baseline BMI (<25 kg/m2) and lower baseline LDL cholesterol (<130 mg/dl) level (Fig. 1).
https://static-content.springer.com/image/art%3A10.1007%2Fs13668-013-0059-x/MediaObjects/13668_2013_59_Fig1_HTML.gif
Fig. 1

Total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and LDL-C to high-density lipoprotein cholesterol (HDL-C) ratio response to nut intake by baseline LDL-C level and body mass index (BMI). Data presented from a pooled analysis study of 25 nut intervention trials, for which the mean serving size was 67 g (2.4 oz) of nuts per day. (Data adapted from Sabaté, et al. JAMA 2010)

A prior meta-analysis evaluated 13 clinical walnut intervention trials that had been conducted with study durations ranging from four to 24 weeks [19], using a range of 5 to 25 % of daily total energy from walnuts. The findings were in concordance with those of the aforementioned pooled analysis, as the walnut-enriched diets were associated with a 6.7 % decrease in LDL cholesterol level as compared to the control diets, and null results were found for HDL cholesterol and TG.

In light of the increased prevalence of obesity among children and adolescents worldwide [20], research is gradually emerging regarding the effect of nuts on the blood lipid profile and microvascular function of obese children and adolescents. A 16-week, randomized, parallel design trial was recently conducted with 17 obese female adolescents to evaluate the effects of supplementing the diet with Brazil nuts [21••]. Subjects in the intervention group consumed 15–25 g per day of Brazil nuts to achieve 10 % of their daily energy requirements from MUFAs. Compared to the placebo group, Brazil nut intake significantly reduced TC, LDL cholesterol and TG levels by 10.5, 16.1 and 17.7 %, respectively. In light of the stable BMI and waist circumference noted during the trial, the investigative team concluded that Brazil nuts are a nutrient-rich whole food that can be used as a supplement to the diet for cardioprotection among obese female adolescents.

Summary Statement for the Effect of Nuts on Blood Lipid Levels

There is consistently strong evidence from both pooled analysis and meta-analysis showing the positive benefits of nut consumption in a dose-dependent manner for the management of blood lipid levels, with greater benefits being achieved among persons with a BMI less than 25 kg/m2 and for those with higher LDL cholesterol (>160 mg/dl) levels. Additional studies are warranted to explore the potential synergistic effect of consuming mixed nuts on blood lipid levels in healthy and hypercholesterolemic individuals.

Effect of Nuts on CVD Risk Factors Beyond the Blood Lipid Profile

As discussed above, nuts are a unique type of plant food that contains a distinctive mix of nutrients and non-nutrient bioactive constituents. Thus, additional cardioprotective benefits from nut consumption beyond improving the blood lipid profile have been extensively studied and summarized by others, specifically on biomarkers of oxidative stress, inflammation and vascular reactivity [2225].

Biomarkers of Oxidative Stress

The majority of nuts contain a moderate to high level of MUFA that is not conducive to oxidation. However, nuts contain PUFA that can act as a substrate for oxidation reactions [26]. Walnuts are notably high in PUFA but they inherently contain antioxidants that can potentially mitigate oxidative reactions in biological membranes. It is worth noting that, to date, no human study using walnuts has found any deleterious effects on oxidative status as compared to healthy diets [25].

Findings from early in vivo studies using nut extracts showed reductions of lipid peroxidation or oxidative DNA damage, which were subsequently followed by short- and long-term experimental animal studies that found beneficial effects on antioxidant enzyme activity and lipid oxidation [10, 23]. Randomized controlled feeding trials of 3–8 weeks in duration that have been conducted in humans using MUFA-rich nuts (e.g., almonds) have found either a reduction in biomarkers of oxidation or null findings [23]. Further, postprandial feeding studies using almonds and walnuts have found either beneficial effects or null findings on postprandial oxidative stress [2730]. More recent evaluations of the postprandial effect of pecan consumption [31•] and a 4-week feeding trial with pistachios [32•] have both shown reductions in LDL oxidation, the former of which confirmed the bioavailability and contribution of bioactive compounds that can confer beneficial antioxidant defense outcomes.

The recent Prevencion con Dieta Mediterranea (PREDIMED) trial randomized 7,477 subjects (age range 55–80 years) who were at high risk for CVD to (1) an energy-unrestricted Mediterranean diet plus extra-virgin olive oil, (2) an energy-unrestricted Mediterranean diet plus 30 g per day mixed nuts (50 % walnuts, 25 % almonds and 25 % hazelnuts), or (3) an energy-unrestricted control, low-fat diet, and evaluated the groups’ oxidized LDL levels after 12 weeks [33]. The PREDIMED investigative team observed that the mixed nut intervention resulted in reduced oxidized LDL levels as compared to the control diet. In contrast to these findings, a parallel design trial using the same mixed nut approach versus a nut-free diet for 12 weeks in 50 adult patients with metabolic syndrome showed null findings for oxidized LDL and other biomarkers, with the exception of reduced DNA damage in the participants consuming the mixed nut diet [34].

Biomarkers of Inflammation

Null findings have resulted in controlled nut feeding trials in humans that have explored the effects of almond, walnuts and mixed nuts on plasma C-reactive protein (CRP); these results have been previously reviewed by others up to 2008 [25]. However, feeding trials using mixed nuts and walnuts alone have found decreased levels of other inflammatory mediators, i.e., intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule (VCAM)-1, and interleukin (IL)-6 [35, 36]. Additionally, we recently compared two doses of almonds in a tightly controlled feeding trial to a healthy control diet and showed that the two almond diets reduced the levels of CRP and E-selectin in the context of null findings for IL-6 [37•].

In light of the walnut’s rich content of the anti-inflammatory fatty acid ALA and the potent phenolic compound ellagic acid, postprandial walnut feeding studies have been conducted in human subjects to evaluate the acute effects of walnut-rich meals and of consuming a walnut-rich, mixed nut diet (over a 3-month period) on the expression of pro-inflammatory molecules in circulating mononuclear cells and/or circulating biomarkers of postprandial inflammation [28, 38, 39]. Walnuts were shown to confer similar or superior postprandial blunting of circulating inflammatory biomarkers, as compared to meals enriched with olive oil [28, 38]. Additionally, walnut-rich meals reduced the postprandial mRNA expression of IL-6 in circulating blood mononuclear cells [38], and consumption of walnut-rich, mixed nuts diets for 3 months reduced monocyte expression of pro-inflammatory ligands [39].

Endothelial Function

Several nutrients exist in all nuts that have the potential to influence vascular reactivity, i.e., tocopherols [40], polyphenols [41] and L-arginine [42], which can counteract the transient endothelial dysfunction that occurs when an SFA-rich meal [43] or diet [4446] is consumed. However, ALA is only found in walnuts and pecans. More specifically, walnuts contain high levels of ALA (2.5 g per 100 g) and pecans contain 0.5 g per 100 g [45].

Three randomized crossover trials have been conducted to evaluate the effect of postprandial and chronic walnut consumption on endothelial function using flow-mediated dilatation (FMD) in the brachial artery [47]; two trials involved subjects with hypercholesterolemia [28, 36] and one trial involved subjects with type 2 diabetes [48••]. Walnuts had beneficial effects on FMD in all three of these trials, which may be due to their high ALA content in the context of their inherently high antioxidant and L-arginine content. Further research using other types of nuts is warranted to determine if their bioactive compounds improve FMD in subjects at high risk of developing CVD.

In light of the consistency of findings showing a beneficial effect from walnut consumption on endothelial function, a specific health claim for walnuts was published in the Official Journal of the European Union in May 2012 [49••]. The walnut-specific health claim states that “Walnuts contribute to the improvement of the elasticity of the blood vessels” and may be used only for food that provides a daily intake of 30 grams of walnuts.

Hypertension and Atrial Fibrillation

The Shanghai Women’s Health Study [50] and the Physicians’ Health Study [51•] have both failed to find an association between hypertension and nut consumption, and null findings have also been observed in the small FMD walnut studies that have been previously described. However, the aforementioned PREDIMED trial is the first adequately powered study that has demonstrated reductions in systolic and diastolic blood pressure after consumption of a Mediterranean diet supplemented with mixed nuts versus a low-fat control diet or a Mediterranean diet supplemented with extra-virgin olive oil [35]. These investigators found that the erythrocyte membranes from the subjects consuming mixed nuts daily had reduced cholesterol to phospholipid ratios, and suggested that this could lead to increased membrane fluidity and antihypertensive effects [52]. Additional studies are needed to further elucidate the antihypertensive mechanism(s) related to nut consumption.

Atrial fibrillation is prevalent in the US and European Union [53, 54], and affects approximately 2.3 million and 4.5 million individuals, respectively. Recent findings from the Physicians’ Health Study have failed to show an association between incident atrial fibrillation and nut consumption [55•]. Additional prospective studies are warranted, as this cohort solely consisted of male physicians who may have been consuming higher amounts of nuts due to their known health benefits.

Summary Statement for the Effect of Nuts on CVD Risk Factors Beyond the Blood Lipid Profile

Strong and relatively consistent evidence from ongoing human studies suggests that MUFA-rich nuts may improve oxidative status, and walnuts (PUFA-rich) have either a slightly beneficial or neutral effect. There is consistent evidence from both acute- and long-term nut trials showing reductions in several inflammatory biomarkers. However, inflammatory biomarkers have been secondary outcomes in clinical trials using nut-enriched diets, with the exception of three postprandial walnut feeding trials. These walnut trials are helping to elucidate the anti-inflammatory effects of nuts at the molecular level; however, additional studies are necessary to further evaluate the mechanisms and constituents in nuts that are contributing to these beneficial outcomes. Limited evidence suggests beneficial effects for nut intake on blood pressure, and evidence is currently lacking for an association between nut consumption and incident atrial fibrillation.

Epidemiologic Studies of Nut Consumption, CHD Risk and Cardiovascular Mortality

In 1992, the Loma Linda University Adventist Health Study-1 (AHS-I) was the first prospective study to report a beneficial effect between a higher frequency of nut intake and reduced CHD incidence in a large cohort of healthy adults (Table 2) [56]. The Nurses’ Health Study [57], Physicians’ Health Study [58], and the Iowa Women’s Health Study [59] subsequently reported similar effects from frequent nut consumption in their large US cohorts, which suggests that frequent nut consumption in the context of a US dietary pattern confers cardioprotection.
Table 2

Epidemiological studies on the frequency of nut intake and relative risk of non-fatal myocardial infarction (MI), coronary heart disease (CHD) death and sudden cardiac death

Reference

Males/Females

Number of years of follow-up

Outcomes

Relative Risk

Adventist Health Study-1

10,003 Males

6

Non-fatal MI

0.52

16,740 Females

CHD death

0.62

Iowa Women’s Health Study

19,411 Females

7

CHD death

0.60

Nurses’ Health Study

86,016 Females

14

Non-fatal MI

0.68

CHD death

0.61

Physicians’ Health Study

21,434 Males

17

Sudden cardiac death

0.53

CHD death

0.77

Combined

153,604

44

CHD death

0.63

A summary of the combined evidence from the four US-based cohort studies was reported for the relative risk (RR) of fatal coronary heart disease (CHD) using the median of each nut frequency consumption category, which showed a 37 % decreased RR for those consuming nuts in the highest frequency intake group (more than four times per week) compared to the lowest nut intake group (never or seldom consume nuts) [60]. Further, a clear dose–response gradient was found in each of the four studies, with an 8.3 % average reduction in RR of CHD death for each weekly serving of nuts. Using multivariate analysis, a more recent pooled analysis of these four studies found a similar RR of 0.65 (95 % CI, 0.47–0.89) between the highest nut intake group and total CHD, and an RR of 0.61 (95 % CI, 0.35–1.05) for fatal CHD among participants consuming nuts five or more times per week [61]. In all four studies, the effect of nut consumption frequency and total CHD or fatal CHD was independent of gender, age, BMI, alcohol intake, smoking, presence of CVD risk factors and nutrient characteristics.

Although the primary aim of the PREDIMED trial was to examine the efficacy of two Mediterranean diets as compared to a low-fat control diet on primary CVD prevention (see next section below), the PREDIMED investigative team conducted an additional longitudinal cohort study on 7,216 of the participants using baseline consumption of six specific types of nuts commonly consumed in Spain. Consumption of these nuts (almonds, peanuts, hazelnuts, pistachios and pine nuts; and, walnuts as a separate food item), treated as the exposure, was evaluated for the following three outcomes: total mortality; cardiovascular mortality only; and, cancer mortality only [62••]. Compared to participants that never consumed nuts, those participants that consumed >3 weekly servings of total nuts, walnuts or other nuts (excluding walnuts) had significant reductions in cardiovascular mortality of 55, 47 and 58 %, respectively. These recent findings are similar to the aforementioned prospective studies that reported significant risk reductions ranging between 30 and 57 % between frequent nut consumption and fatal CHD [5659], and the pooled analysis that reported a 39 % reduction for fatal CHD [61].

Summary Statement for Epidemiologic Studies of Nut Consumption, CHD Risk and Cardiovascular Mortality

Strong and consistent evidence from four large US epidemiologic studies conducted over the past two decades has shown an association between the increased frequency of weekly nut intake and reduced CHD risk. The pooled data from these studies supports the recommendation for frequent nut intake to reduce CHD risk among the US population. The PREDIMED trial, which featured a large prospective cohort outside of the US, also found similar beneficial outcomes between the frequency of nut intake and diminished CHD risk and cardiovascular mortality.

Nuts and Primary and Secondary Prevention of CVD

The findings reported by the PREDIMED team have provided support for the use of nuts in the primary prevention of CVD among high-risk individuals [63••]. The PREDIMED trial’s primary endpoint was the combination of the rate of several major cardiovascular events, i.e., myocardial infarction, stroke or cardiovascular death. Compared to the low-fat control group, a multivariable adjusted hazard ratio (HR) of 0.72 (95 % CI, 0.54–0.96) was observed for the group assigned to consumption of a Mediterranean diet with mixed nuts, and an HR of 0.70 (95 % CI 0.54–0.92) was found for the group assigned to consumption of a Mediterranean diet with extra-virgin olive oil. The results of this landmark trial have significant public health implications in light of the lack of energy restrictions during the trial and the challenges of individuals struggling with weight management for the primary prevention of CVD.

The findings of the PREDIMED trial complement those of the Lyon Diet Heart Study, which was a secondary CHD prevention trial that suggested that an unrestricted-energy Mediterranean diet rich in ALA (found in high levels in walnuts) could reduce the risk of recurrence [64]. Specifically, supplementation of the Mediterranean diet (rich in oleic acid/MUFA, low in SFA, and low in n-6 fatty acids) with 1 g per day of very long-chain n-3 fatty acids was associated with a 50–70 % reduced risk of recurrence after 4 years of follow-up among participants with CHD. Similar findings were noted in the Cholesterol and Recurrent Events (CARE) Study, which evaluated the cardio-protective effect of frequent nut consumption in a population that had previously experienced a non-fatal myocardial infarction [65]. These investigators found that those consuming greater than one serving of nuts per week experienced a 25 % reduced risk of total CHD compared to those who rarely consumed nuts or consumed less than one serving per month.

Summary Statement for Nuts and Primary and Secondary Prevention of CVD

A recent large trial conducted in Spain (PREDIMED) was very successful in using an unrestricted-energy Mediterranean-type background diet with mixed nuts for the primary prevention of CVD. Further, use of an ALA supplement or frequent nut consumption has been shown to prevent recurrent CHD events. Hence, it is of paramount importance to design public health messages regarding the appropriate use of nut-based dietary patterns or fatty acid dietary strategies for the primary and secondary prevention of CVD. In light of an ALA supplement having been found to be effective in a secondary prevention trial, a future trial to evaluate the effects of a walnut-enriched, unrestricted-energy Mediterranean diet would be of interest to evaluate whether daily walnut intake could achieve similar or heightened findings.

Conclusions

Significant evidence has accumulated demonstrating the cardioprotective benefits from frequent nut consumption, beginning with the findings from the 1992 Loma Linda University AHS-I to the 2013 release of the PREDIMED trial results. Nuts are nutrient-dense whole plant foods that have the potential for the primary and secondary prevention of CVD and reducing cardiovascular mortality. Government funded trials are warranted to determine the synergistic potential of nuts on CVD biomarkers and outcomes using a variety of background dietary patterns and combinations of nuts. Public health messages recommending frequent nut intake should be framed in the context of the findings from amply powered trials, and should consider the populations evaluated and their respective background dietary patterns.

Compliance with Ethics Guidelines

Conflict of Interest

Joan Sabaté has received previous research grant support from the California Walnut Commission and the National Peanut Board.

Michelle Wien has received previous research grant support from the Almond Board of California.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Copyright information

© Springer Science+Business Media New York 2013